drugset / Trial / NCT01601704

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704

Phase 3 Terminated 8910 enrolled Orexigen Therapeutics, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and obese subjects who are at a higher risk of having these events because they have diabetes and/or other cardiovascular risk factors.

Timeline

Start
2012-06
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 360 mg
Subject Naltrexone Small molecule 32 mg

Indications